Neuroscience isn't currently one of the top strategic R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting. The UK-headquartered pharma group is ...
Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson's disease, licensing a bispecific antibody from South Korea's ABL Bio in a deal that could be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results